This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. VCEL, QDEL, BEAM, SEM, ARDT, PACS, ENOV, NVCR, LMAT, and BLTEShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Vericel (VCEL), QuidelOrtho (QDEL), Beam Therapeutics (BEAM), Select Medical (SEM), Ardent Health (ARDT), PACS Group (PACS), Enovis (ENOV), NovoCure (NVCR), LeMaitre Vascular (LMAT), and Belite Bio (BLTE). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Its Competitors Vericel QuidelOrtho Beam Therapeutics Select Medical Ardent Health PACS Group Enovis NovoCure LeMaitre Vascular Belite Bio Lionheart Acquisition Co. II (NASDAQ:LCAP) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings. Which has better valuation & earnings, LCAP or VCEL? Vericel has higher revenue and earnings than Lionheart Acquisition Co. II. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLionheart Acquisition Co. IIN/AN/A$3.21MN/AN/AVericel$237.22M7.50$10.36M$0.031,178.00 Does the media favor LCAP or VCEL? In the previous week, Vericel had 7 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 7 mentions for Vericel and 0 mentions for Lionheart Acquisition Co. II. Vericel's average media sentiment score of 0.91 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Vericel is being referred to more favorably in the news media. Company Overall Sentiment Lionheart Acquisition Co. II Neutral Vericel Positive Which has more volatility and risk, LCAP or VCEL? Lionheart Acquisition Co. II has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Do analysts rate LCAP or VCEL? Vericel has a consensus price target of $61.14, indicating a potential upside of 73.01%. Given Vericel's stronger consensus rating and higher probable upside, analysts clearly believe Vericel is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LCAP or VCEL more profitable? Vericel has a net margin of 1.25% compared to Lionheart Acquisition Co. II's net margin of 0.00%. Vericel's return on equity of 1.09% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Lionheart Acquisition Co. IIN/A -44.30% 1.39% Vericel 1.25%1.09%0.73% SummaryVericel beats Lionheart Acquisition Co. II on 10 of the 11 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LCAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$497.50M$162.57M$5.55B$9.40BDividend YieldN/AN/A3.75%4.03%P/E RatioN/A0.6328.0119.82Price / SalesN/A24.07432.8198.20Price / Cash20.6411.7036.1658.27Price / Book-9.463.508.125.65Net Income$3.21M$1.30M$3.25B$257.91M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$26.96-0.1%N/A+6,087.3%$497.50MN/A0.003VCELVericel3.6761 of 5 stars$40.17+1.9%$61.14+52.2%-31.0%$1.98B$237.22M1,339.45300News CoverageQDELQuidelOrtho4.4492 of 5 stars$30.82+5.5%$44.33+43.8%-23.3%$1.98B$2.78B-6.206,600News CoverageGap UpBEAMBeam Therapeutics2.0037 of 5 stars$20.30+5.8%$48.75+140.1%-18.5%$1.93B$63.52M-4.40510Gap UpHigh Trading VolumeSEMSelect Medical5 of 5 stars$14.86+0.3%$26.00+75.0%-62.3%$1.90B$5.19B11.0944,100News CoverageARDTArdent Health3.3954 of 5 stars$13.77+3.5%$20.67+50.1%N/A$1.90B$5.97B8.4524,900News CoverageAnalyst DowngradePACSPACS Group2.8115 of 5 stars$12.95+3.8%$34.29+164.8%-63.7%$1.90B$3.11B0.0032,433News CoverageENOVEnovis2.6987 of 5 stars$34.74+5.2%$55.60+60.0%-44.0%$1.89B$2.11B-2.497,367News CoverageNVCRNovoCure3.5741 of 5 stars$17.51+3.7%$32.43+85.2%-13.3%$1.88B$605.22M-11.601,488News CoverageUpcoming EarningsLMATLeMaitre Vascular2.7017 of 5 stars$83.91+1.1%$97.83+16.6%-6.5%$1.87B$219.86M42.38490News CoveragePositive NewsBLTEBelite Bio1.8346 of 5 stars$60.12+2.5%$96.67+60.8%+25.2%$1.87BN/A-44.2110High Trading Volume Related Companies and Tools Related Companies VCEL Alternatives QDEL Alternatives BEAM Alternatives SEM Alternatives ARDT Alternatives PACS Alternatives ENOV Alternatives NVCR Alternatives LMAT Alternatives BLTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
